The Chiron Approach to (3R,3aS,6aR)-Hexahydrofuro[2,3-b]furan-3-ol, a Key Subunit of HIV-1 Protease Inhibitor Drug, Darunavir
Author(s) -
Arun K. Ghosh,
Shivaji B. Markad,
William L. Robinson
Publication year - 2020
Publication title -
the journal of organic chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.2
H-Index - 228
eISSN - 1520-6904
pISSN - 0022-3263
DOI - 10.1021/acs.joc.0c02396
Subject(s) - darunavir , chemistry , enantioselective synthesis , stereochemistry , furan , hiv 1 protease , stereoselectivity , derivative (finance) , anomer , combinatorial chemistry , human immunodeficiency virus (hiv) , catalysis , organic chemistry , protease , enzyme , medicine , family medicine , viral load , antiretroviral therapy , financial economics , economics
We describe an enantioselective synthesis of (3 R ,3 aS ,6 aR )-hexahydrofuro[2,3- b ]furan-3-ol which is a key subunit of darunavir, a widely used HIV-1 protease inhibitor drug for the treatment of HIV/AIDS patients. The synthesis was achieved in optically pure form utilizing commercially available sugar derivatives as the starting material. The key steps involve a highly stereoselective substrate-controlled hydrogenation, a Lewis acid catalyzed anomeric reduction of a 1,2- O -isopropylidene-protected glycofuranoside, and a Baeyer-Villiger oxidation of a tetrahydrofuranyl-2-aldehyde derivative. This optically active ligand alcohol was converted to darunavir efficiently.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom